PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
The value of the depression market in France is expected to fall following patent expiries for Lundbeck’s Lexapro in 2014, Eli Lilly’s Cymbalta in 2014, Otsuka Pharmaceutical/BMS’s Abilify in 2014, and AstraZeneca’s Seroquel XR in 2017. GlobalData estimates the drug sales for MDD in Germany were approximately $236.7m in 2013. GlobalData expects Eli Lilly’s Cymbalta and Lundbeck’s Brintellix to be the top-selling products by the end of the forecast period in Italy. GlobalData anticipates seven products in the late-stage pipeline to enter the MDD market in Spain during the forecast period: four adjunctive therapies, and three other antidepressant therapies. If physicians in the UK become convinced from experience in clinical practice that Brintellix offers improvements in cognitive function, Lundbeck will be able to differentiate Brintellix from other available SSRI and SNRI treatments and subsequently drive higher patient share.
Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in 5EU from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Major depressive disorder market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in 5EU.
Sales for Major Depressive Disorder (MDD) inthe Five Major EU Markets
GlobalData estimates the drug sales for MDD in2013 were approximately $1.2 billion in the 5EUcovered in this forecast. By the end of the forecastperiod in 2023, sales will grow to approximately$1.3 billion with a Compound Annual Growth Rate(CAGR) of 0.72%.
The growth of the MDD market in the 5EU is drivenby:
The expected launch of Lundbeck/Takeda’sBrintellix
The introduction of four adjunctive therapiesand three other antidepressant therapiesduring the forecast period
Increasing prevalent cases of MDDThe barriers to the growth of MDD market in the5EU are:
Key branded drug patent expiries leading tosales erosion